secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0000939767-24-000062
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis sues Cipla over generic Cabometyx patents covering 20mg, 40mg strengths
--------------------------------------------------------------------------------

- Cipla amended its ANDA to seek approval for 20mg and 40mg generic cabozantinib, adding Paragraph IV certifications.
- Exelixis filed a patent infringement complaint on May 9, 2024 in Delaware federal court.
- Five patents asserted: U.S. Patent Nos. 8,877,776, 11,091,439, 11,091,440, 11,098,015, 11,298,349.
- Exelixis seeks order that FDA approval be no earlier than the latest patent expiration on February 10, 2032.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976724000062/0000939767-24-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976724000062/exel-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000939767-24-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer